Johnson & Johnson’s (J&J) Tremfya (guselkumab) has recently been granted approval for the...
- Tremfya approval: increasing options for psoriasis treatment
- Pfizer funds CreakyJoints’ initiative for shared decision making in rheumatoid arthritis
- World Immunisation Week 2018: WHO spotlights remaining vaccine coverage gaps
- FDA committee supports first-ever approval of cannabis epilepsy drug
- PhRMA report reveals 537 neurological drugs currently in development
Tremfya approval: increasing options for psoriasis treatment
Johnson & Johnson’s (J&J) Tremfya (guselkumab) has recently been granted approval for the treatment of adults suffering from moderate-to-severe plaque psoriasis in Australia, Brazil, and Japan. J&J has licensed Tremfya to MorphoSys in these respective regions.
Pfizer funds CreakyJoints’ initiative for shared decision making in rheumatoid arthritis
In a landmark moment for rheumatoid arthritis (RA) treatment, Pfizer has joined forces with CreakyJoints, an online patient advocacy group, in an initiative to improve shared decision making about treatment options.
World Immunisation Week 2018: WHO spotlights remaining vaccine coverage gaps
Each year, the World Health Organization (WHO) uses World Immunisation Week during the last week of April to promote awareness of the countless benefits of vaccines, which are undeniably the world’s most effective and economically sound medical intervention.
FDA committee supports first-ever approval of cannabis epilepsy drug
The Peripheral and Central Nervous System Drugs Advisory Committee of the US Food and Drug Administration (FDA) has unanimously recommended supporting the approval of a cannabis-based epilepsy drug.
PhRMA report reveals 537 neurological drugs currently in development
A report by Pharmaceutical Research and Manufacturers of America (PhRMA) has found that over 500 medicines for neurological disorders are currently in development.
Adocia to begin trial of blood sugar regulation technology
French biotech Adocia has announced the initiation of a Phase I study of BioChaperone Pramlintide Insulin, a treatment that could better regulate glucose levels in type 1 diabetes patients.
Sempre Health and Novo Nordisk to partner to lower diabetes drug cost
Sempre Health has announced that it is collaborating with Novo Nordisk on a pilot programme aimed at delivering cheaper diabetes drugs to patients.
Novo Nordisk and Red Cross to tackle NCDs in humanitarian crises
Pharmaceutical company Novo Nordisk has announced it will work with The International Committee of the Red Cross (ICRC) and the Danish Red Cross (DRC) to tackle chronic care in humanitarian crises.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.